Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C126798
http://purl.obolibrary.org/obo/NCIT_C126798
|
|---|---|
| Preferred Name | Pidnarulex |
| Definitions |
An orally bioavailable inhibitor of RNA polymerase I (Pol I), with potential antineoplastic activity. Upon oral administration, pidnarulex selectively binds to and inhibits Pol I, prevents Pol I-mediated ribosomal RNA (rRNA) synthesis, induces apoptosis, and inhibits tumor cell growth. Pol I, the multiprotein complex that synthesizes rRNA, is upregulated in cancer cells and plays a key role in cell proliferation and survival. Hyperactivated rRNA transcription is associated with uncontrolled cancer cell proliferation.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally bioavailable inhibitor of RNA polymerase I (Pol I), with potential antineoplastic activity. Upon oral administration, pidnarulex selectively binds to and inhibits Pol I, prevents Pol I-mediated ribosomal RNA (rRNA) synthesis, induces apoptosis, and inhibits tumor cell growth. Pol I, the multiprotein complex that synthesizes rRNA, is upregulated in cancer cells and plays a key role in cell proliferation and survival. Hyperactivated rRNA transcription is associated with uncontrolled cancer cell proliferation. |
|---|---|
| prefLabel | Pidnarulex
|
| label | Pidnarulex
|
| PDQ_Closed_Trial_Search_ID | 780145
|
| code | C126798
|
| prefixIRI | NCIT:C126798
|
| in_subset | |
| Preferred_Name | Pidnarulex
|
| FDA_UNII_Code | 3R4C5YLB9I
|
| Contributing_Source | FDA
|
| Maps_To | Pol I Inhibitor CX5461
|
| CAS_Registry | 1138549-36-6
|
| NCI_Drug_Dictionary_ID | 780145
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 780145
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C3180849
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |